7th GO & 7th MEMAGO
Middle East & Mediterranean Association of Gynecologic Oncologist
December 7-8, 2023
Egypt
www.memago.org
BOARD of DIRECTORS

PRESIDENT
Ali Ayhan, TURKEY

VICE PRESIDENT
Mehmet Faruk Köse, TURKEY

SECRETARY
Mehmet Mutlu Meydanlı, TURKEY

TREASURER
Çağatay Taşkıran, TURKEY

MEMBER
Nejat Özgül, TURKEY
Mete Güngör, TURKEY
Müfit Cemal Yenen, TURKEY
Hüsnü Çelik, TURKEY

CO-PRESIDENT
Georges Chahine, LEBANON

CO-VICE PRESIDENT
Muhieddine Seoud, LEBANON

CO-SECRETARY
David Atallah, LEBANON

CO-TREASURER
Monia Hechiche, TUNISIA

CO-MEMBER
Basel Refky, EGYPT
Waleed El Jassar, KUWAIT
Karim El Masri, U.A.E.
Jamel Ben Hassouna, TUNISIA

7th MEMAGO
Middle East & Mediterranean Association of Gynecologic Oncologists

December 7-8, 2023
Egypt
|--------|------------------------------------------------------|---------------------------------------------------------|----------------------------------------|----------------------------------------------------------|--------------------------------------------------------|
| 09h30-10h00 | Welcome and introduction | 11h15-11h35 Early-stage cervical cancer: Is less radical surgery better?  
11h15-11h25 Yes  
11h25-11h35 No | 14h20-14h50 Highlights from ESGO 2023 | 17h20-17h35 Adjuvant treatment of endometrial cancer: Molecular subtypes and treatment implications | 17h20-17h35 Adjuvant treatment of endometrial cancer: Molecular subtypes and treatment implications |
| 10h00-10h20 | Screening for cervical cancer: Has MEMAGO adapted? | 11h35-11h55 Minimally invasive surgery (MIS) for early-stage cervical cancer: The ongoing debate  
11h35-11h45: It is still safe  
11h45-11h55: It should not be the standard of care | 14h50-15h20 Highlights from IGCS 2023 | 15h35-15h55 The changing classification and staging of endometrial cancer | 17h35-17h50 Paradigm changes in the treatment of advanced and recurrent endometrial cancer |
| 10h20-10h40 | HPV vaccines: Real world efficacy | 11h55-12h15 Adjuvant treatment of intermediate-risk cervical cancer patients: Can we do more?  
12h15-12h35 Neoadjuvant therapy for the management of bulky (> 4cm) tumors  
12h15-12h25 PRO  
12h25-12h35 CON | 15h20-15h35 Discussion | 15h55-16h15 Fertility sparing strategies in early endometrial cancer: How to optimize patients’ selection?  
16h15-16h35 Updates in the management of early endometrial cancer  
16h35-16h55 Uterine manipulator during MIS for endometrial cancer: Is it safe? | 18h10-18h25 Updates on adjuvant treatment of uterine sarcoma |
| 10h40-11h00 | Can cervical cancer be eliminated in the MEMAGO region:  
How best to combine screening and vaccination? | 16h55-17h05 Discussion | 15h20-15h35 Discussion | 16h55-17h05 Discussion | 18h25-18h40 Discussion |
| 11h00-11h15 | Discussion | 17h05-17h20 COFFEE BREAK | 15h20-15h35 Discussion | 17h05-17h20 COFFEE BREAK | 18h25-18h40 Discussion |

**PROGRAM**

**Thursday 7th, December 2023**

**9h30-10h00** Welcome and introduction  
MEMAGO President  
EGOS Chair  

**10h00-10h20** Screening for cervical cancer: Has MEMAGO adapted?  

**10h20-10h40** HPV vaccines: Real world efficacy  

**10h40-11h00** Can cervical cancer be eliminated in the MEMAGO region:  
How best to combine screening and vaccination?  

**11h00-11h15** Discussion  

**11h15-11h35** Early-stage cervical cancer: Is less radical surgery better?  
11h15-11h25 Yes  
11h25-11h35 No  

**11h35-11h55** Minimally invasive surgery (MIS) for early-stage cervical cancer: The ongoing debate  
11h35-11h45: It is still safe  
11h45-11h55: It should not be the standard of care  

**11h55-12h15** Adjuvant treatment of intermediate-risk cervical cancer patients: Can we do more?  

**12h15-12h35** Neoadjuvant therapy for the management of bulky (> 4cm) tumors  
12h15-12h25 PRO  
12h25-12h35 CON  

**12h35-12h55** Updates for the management of advanced and recurrent cervical cancer  

**12h55-13h10** Surgery in locally advanced and in residual disease post concurrent chemoradiotherapy  

13h10-13h20 Discussion  

13h20-14h20 LUNCH  

**14h20-14h50** Highlights from ESGO 2023  

**14h50-15h20** Highlights from IGCS 2023  

**15h20-15h35** Discussion  

**15h35-15h55** The changing classification and staging of endometrial cancer  

**15h55-16h15** Fertility sparing strategies in early endometrial cancer: How to optimize patients’ selection?  

**16h15-16h35** Updates in the management of early endometrial cancer  

**16h35-16h55** Uterine manipulator during MIS for endometrial cancer: Is it safe?  

17h05-17h20 COFFEE BREAK  

**17h20-17h35** Adjuvant treatment of endometrial cancer: Molecular subtypes and treatment implications  

**17h35-17h50** Paradigm changes in the treatment of advanced and recurrent endometrial cancer  

**17h50-18h10** Principles of surgery in uterine sarcomas  

**18h10-18h25** Updates on adjuvant treatment of uterine sarcoma  

18h25-18h40 Discussion  

---

**EGOS**  
**C.A.I.R.O Journal Club**  
**Middle East & Mediterranean Association of Gynecologic Oncologist**

**MEMAGO**
### Session 1 Epithelial Ovarian Cancer (EOC) - I

- **9h30-9h50** Molecular profile and classification of EOC
- **9h50-10h10** Updates in the management of borderline ovarian tumors
- **10h10-10h30** Management of low-grade serous carcinoma
- **10h30-10h50** Fertility sparing options in EOC
- **10.50-11h10** Immunotherapy and Antibody Drug Conjugates (ADCs): How far are we from clinical application?
- **11h10-11h30** Discussion

### Session 2 Debates in EOC

- **13h00-13h30** Neoadjuvant chemotherapy vs. primary cytoreduction in EOC (Presidential talk)
- **13h30-14h00** What is the appropriate approach for the management of recurrent EOC?
  - **13h30-13h45**: Surgery (DESKTOP III & SOC-1)
  - **13h45-14h00**: Chemotherapy (GOG 213)
- **14h00-14h20** Is there still a role for HIPEC in the frontline management of advanced EOC?
  - **14h00-14h10**: Yes
  - **14h10-14h20**: No
- **14h20-14h30** Discussion

### Session 3 Epithelial Ovarian Cancer (EOC) – II

- **15h30-15h50** Genetic testing and counselling in a limited resource setting
- **15h50-16h10** Choice of regimens in the first line setting: PARP alone or combination?
- **16h10-16h30** Recurrent EOC after PARP: What does the evidence say?
- **16h30-16h45** MEMAGO consensus in EOC: The Roadmap
- **16h45-17h00** Discussion

### Session 4 Real World Data from the MEMAGO Region

- **17h15-17h25** Cervical Cancer
- **17h25-17h35** Endometrial Cancer
- **17h35-17h45** Ovarian Cancer
- **17h45-17h55** Gestational Trophoblastic Neoplasia
- **17h55-18h05** Vulvar Cancer
- **18h05-18h15** Discussion
- **18h15-18h30** Closing Ceremony